Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tapestry to cut non-clinical work force
The biopharmaceutical company expects to eliminate 14 positions including executive and non-executive employees in all areas of operations. All clinical development staff will remain with the company. Tapestry
The biopharmaceutical company expects to eliminate 14 positions including executive and non-executive employees in all areas of operations. All clinical development staff will remain with the company. Tapestry
Research teams at the Imperial College of London, in collaboration with the UK-based MDEX Consortium will conduct the trial of AVI-4658 for AVI in the UK. The proof-of-principle
Nearly 1300 epilepsy patients, aged between 16 and 70 years, will take part in three trials. Two studies are designed to evaluate the efficacy and safety of brivaracetam
Ronald Zarrella, chairman and CEO of Bausch & Lomb, said: “With a strong and supportive partner in Warburg Pincus, we are well-positioned to create new opportunities for Bausch
The company will launch its product immediately under the tradename TriLegest Fe (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets). The company’s generic oral contraceptive
CHDI’s funding builds upon an earlier successful collaboration between Isis and CHDI, in which CHDI provided Isis with funding for studies that demonstrated the feasibility of using antisense
According to the researchers: “Treatment with thymosin beta 4 resulted in increased re-epithelialization and considerable capillary in-growth. Vessel counts showed a significant increase in the number of vessels
The main objective of this trial is to evaluate the analgesic efficacy of nalbuphine extended release (ER). There are approximately 135 patients with chronic pain secondary to osteoarthritis
Neuro-Therapy Clinic, is owned and operated by Daniel Hoffman, upon board approval, Dr Hoffman will be appointed chief medical officer of CNS Response. Len Brandt, chairman and CEO
In June 2007, GlaxoSmithKline (GSK) announced the launch of a randomized, double-blind, and placebo-controlled Phase III clinical trial in lung cancer to evaluate the MAGE-A3 Antigen-Specific Cancer Immunotherapeutic